NCT03293654View on ClinicalTrials.gov

A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

May 29, 2019

Study Completion Date

May 29, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

MB02

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

DRUG

US licenced Avastin®

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

DRUG

EU approved Avastin®

Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

Trial Locations (2)

HA1 3UJ

PAREXEL International - Northwick Park Hospital, Harrow

LS2 9LH

Covance Clinical Research Unit Limited, Leeds

All Listed Sponsors
lead

mAbxience Research S.L.

INDUSTRY

NCT03293654 - A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers | Biotech Hunter | Biotech Hunter